Identification of LMO2 transcriptome and interactome in diffuse large B-cell,lymphoma

Blood

Volumn 119, Issue 23, 2012, Pages 5478-5491

  Cubedo, Elena ^a   Gentles, Andrew J ^b   Huang, Chuanxin ^c   Natkunam, Yasodha ^b   Bhatt, Shruti ^a   Lu, Xiaoqing ^a   Jiang, Xiaoyu ^a   Romero Camarero, Isabel ^d   Freud, Aharon ^b   Zhao, Shuchun ^b   Bacchi, Carlos E ^e   Martínez Climent, Jose A ^f   Sanchez García, Isidro ^d   Melnick, Ari ^c   Lossos, Izidore S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e CSIC/Universidad de Salamanca ^*  (Brazil)

^f UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; HEB PROTEIN; LDB1 PROTEIN; LMO2 PROTEIN; LYL1 PROTEIN; LYMPHOID ENHANCER FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR TAL1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; CENTROMERE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; EMBRYO; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MITOSIS; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84862518017     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403154     Document Type: Article

References (51)

1. Boehm T, Foroni L, Kennedy M, Rabbitts TH. The rhombotin gene belongs to a class of transcriptional regulators with a potential novel protein dimerisation motif. Oncogene. 1990;5(7):1103-1105.
2. Saaposnchez-García I, Axelson H, Rabbitts TH. Functional diversity of LIM proteins: amino-terminal activation domains in the oncogenic proteins RBTN1 and RBTN2. Oncogene. 1995;10(7):1301-1306.
3. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A. 2000;97(1):320-324.
4. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A. 1998;95(7):3890-3895. (Pubitemid 28173224)
5. Li L, Jothi R, Cui K, et al. Nuclear adaptor Ldb1 regulates a transcriptional program essential for the maintenance of hematopoietic stem cells. Nat Immunol. 2011;12(2):129-136.
6. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78(1):45-57. (Pubitemid 24228299)
7. Yamada Y, Pannell R, Forster A, Rabbitts TH. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. Oncogene. 2002;21(9):1309-1315. (Pubitemid 34214496)
8. Deleuze V, Chalhoub E, El-Hajj R, et al. TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. Mol Cell Biol. 2007;27(7):2687-2697. (Pubitemid 46581358)
9. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997;16(11):3145-3157.
10. Lahlil R, Lecuyer E, Herblot S, Hoang T. SCL assembles a multifactorial complex that determines glycophorin A expression. Mol Cell Biol. 2004;24(4):1439-1452. (Pubitemid 38167068)
11. Goardon N, Lambert JA, Rodriguez P, et al. ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J. 2006;25(2):357-366. (Pubitemid 43152856)
12. Curtis DJ, McCormack MP. The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2010;16(23):5618-5623.
13. Schuh AH, Tipping AJ, Clark AJ, et al. ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis. Mol Cell Biol. 2005;25(23):10235-10250.
14. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol. 2003;23(24):9003-9013. (Pubitemid 37499791)
15. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A. 1991;88(10):4367-4371. (Pubitemid 21914541)
16. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science. 2003; 299(5606):495. (Pubitemid 36135119)
17. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10):3520-3529.
18. Fisch P, Boehm T, Lavenir I, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 1992;7(12):2389-2397.
19. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene. 1995;11(5):853-862.
20. McCormack MP, Young LF, Vasudevan S, et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science. 2010;327(5967):879-883.
21. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol. 2000;1(2):138-144.
22. Ono Y, Fukuhara N, Yoshie O. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J Biol Chem. 1997;272(7):4576-4581. (Pubitemid 27078539)
23. Ono Y, Fukuhara N, Yoshie O. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. Mol Cell Biol. 1998;18(12):6939-6950. (Pubitemid 28533015)
24. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
25. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837. (Pubitemid 38917249)
26. Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010;115(3):570-580.
27. Janknecht R, Ernst WH, Pingoud V, Nordheim A. Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J. 1993;12(13):5097-5104. (Pubitemid 23358499)
28. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinalcenter B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636-1642. (Pubitemid 46239598)
29. Jiang X, Lu X, McNamara G, et al. HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. Blood. 2010;116(24):5217-5227.
30. Meier N, Krpic S, Rodriguez P, et al. Novel binding partners of Ldb1 are required for haematopoietic development. Development. 2006;133(24):4913-4923.
31. Leaposcuyer E, Herblot S, Saint-Denis M, et al. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood. 2002;100(7):2430-2440.
32. Song J, Ugai H, Nakata-Tsutsui H, et al. Transcriptional regulation by zinc-finger proteins Sp1 and MAZ involves interactions with the same ciselements. Int J Mol Med. 2003;11(5):547-553.
33. van de Wetering M, Oosterwegel M, Dooijes D, Clevers H. Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J. 1991;10(1):123-132.
34. Gutierrez A Jr, Tschumper RC, Wu X, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010;116(16):2975-2983.
35. Fujiwara T, Lee HY, Sanalkumar R, Bresnick EH. Building multifunctionality into a complex containing master regulators of hematopoiesis. Proc Natl Acad Sci U S A. 2010;107(47):20429-20434.
36. Draheim KM, Hermance N, Yang Y, Arous E, Calvo J, Kelliher MA. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice. Oncogene. 2011;30(10):1252-1260.
37. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer. 2002;2(11):815-825. (Pubitemid 37328900)
38. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol. 2005;7(11):1140-1146.
39. Schneider EM, Torlakovic E, Stuhler A, Diehl V, Tesch H, Giebel B. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma. J Pathol. 2004;204(5):538-545. (Pubitemid 39585952)
40. Kuppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003;111(4):529-537. (Pubitemid 36228010)
41. Baer R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol. 1993;4(6):341-347.
42. Miyamoto A, Cui X, Naumovski L, Cleary ML. Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Mol Cell Biol. 1996;16(5):2394-2401. (Pubitemid 26123761)
43. Schoetz U, Cervelli M, Wang YD, Fiedler P, Buerstedde JM. E2A expression stimulates Ig hypermutation. J Immunol. 2006;177(1):395-400. (Pubitemid 43939151)
44. Quong MW, Harris DP, Swain SL, Murre C. E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. EMBO J. 1999;18(22):6307-6318. (Pubitemid 29533235)
45. Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633-643.
46. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6(11):1079-1086. (Pubitemid 41541785)
47. Goldfarb AN, Flores JP, Lewandowska K. Involvement of the E2A basic helix-loop-helix protein in immunoglobulin heavy chain class switching. Mol Immunol. 1996;33(11-12):947-956. (Pubitemid 26396448)
48. Oram SH, Thoms JA, Pridans C, et al. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients. Oncogene. 2010;29(43):5796-5808.
49. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106(12): 3940-3947. (Pubitemid 41739035)
50. Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205(3):515-522. (Pubitemid 351439299)
51. Spaulding C, Reschly EJ, Zagort DE, et al. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood. 2007;110(7):2650-2658. (Pubitemid 47523189)